Articles

Central nervous system objective responses were observed in patients with HER2-positive metastatic breast cancer treated with neratinib in 3 separate clinical trials. Read More ›

Despite the fragmented nature of the U.S. care delivery and payment system, disparate healthcare stakeholders continue to seek areas of alignment in reducing inefficiencies and enhancing value-driven oncology care. Read More ›

The development and implementation of validated, evidence-based oncology navigation measures are an integral component of broader efforts to promote patient-centric, value-based cancer care. Read More ›

The Oncology Care Model was designed to provide higher quality, more highly coordinated oncology care at the same or lower cost to Medicare. As the program matures, new data is expected to provide insight on the achievement of that ambitious goal. Read More ›

Development and optimization of patient support programs requires organizational alignment and a comprehensive understanding of the payment and care delivery ecosystem in cancer. Read More ›

As the number of people living with cancer continues to increase, so does the need for advocacy, education, and safety net programs to help patients afford the cost of care. Read More ›

After 7 years of follow-up, sustained progression-free survival and overall survival rates were seen with ibrutinib, as well as stable or improved complete response rates over time. Read More ›

informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines. Read More ›

Although ibrutinib is generally cost-effective in first-line use compared with chemotherapy and chemoimmunotherapy, a subset of ibrutinib-treated patients with cardiovascular events had a mitigating impact on the total cost of care. Read More ›

In a phase 3 study, the combination of ibrutinib and rituximab provided superior progression-free survival and overall survival relative to the combination of fludarabine, cyclophosphamide, and rituximab for younger patients with previously untreated chronic lymphocytic leukemia (CLL) Read More ›